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Aim: The Danish National Multiple Myeloma Registry (DMMR) is a population-based clinical 
quality database established in January 2005. The primary aim of the database is to ensure that 
diagnosis and treatment of plasma cell dyscrasia are of uniform quality throughout the country. 
Another aim is to support research. Patients are registered with their unique Danish personal 
identification number, and the combined use of DMMR, other Danish National registries, and 
the Danish National Cancer Biobank offers a unique platform for population-based translational 
research.
Study population: All newly diagnosed patients with multiple myeloma (MM), smoldering 
MM, solitary plasmacytomas, and plasma cell leukemia in Denmark are registered annually; 
~350 patients. Amyloid light-chain amyloidosis, POEMS syndrome (polyneuropathy, organo-
megaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), monoclonal 
gammopathy of undetermined significance and monoclonal gammopathy of undetermined 
significance with polyneuropathy have been registered since 2014.
Main variables: The main registered variables at diagnosis are patient demographics, baseline 
disease characteristics, myeloma-defining events, clinical complications, prognostics, first- and 
second-line treatments, treatment responses, progression free, and overall survival.
Descriptive data: Up to June 2015, 2,907 newly diagnosed patients with MM, 485 patients 
with smoldering MM, 64 patients with plasma cell leukemia, and 191 patients with solitary 
plasmacytomas were registered. Registration completeness of new patients is ~100%. A data 
validation study performed in 2013–2014 by the Danish Myeloma Study Group showed >95% 
data correctness.
Conclusion: The DMMR is a population-based data validated database eligible for clinical, 
epidemiological, and translational research.
Keywords: Multiple Myeloma Registry, population-based, treatment response, progression-
free survival, overall survival
Aim of the database
The Danish National Multiple Myeloma Registry (DMMR) is a population-based 
clinical quality database. DMMR was established on January 1, 2005, to collect clini-
cal data on all newly diagnosed patients with symptomatic multiple myeloma (MM), 
smoldering MM (SMM), plasma cell leukemia (PCL), and osseous and extraosseous 
solitary plasmacytoma. Data were collected from all hematological departments in 
Denmark. The database is funded by the Danish Health Care Regions. The departments 
of hematology and hospitals are obligated to report data on all diagnosed patients to 
the database. The Danish Health Care Regions established the registry as a safeguard 
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for the regional governmental health care quality in Denmark. 
The aim is to ensure that diagnosis and treatment of plasma 
cell dyscrasia are of uniform quality throughout the coun-
try, which has been shown to be the case. Annual reports in 
Danish are published by the Danish Myeloma Study Group 
(DMSG). These reports are available at the DMSG website 
(www.myeloma.dk).
Another aim of the database is to support preclinical, 
clinical, and epidemiological research, and for these pur-
poses, the database is unique because it is population based 
and has a high completeness of data. Quality assessment of 
the registered patients in the database is done by identity 
match with patients registered in the Danish Pathology 
Diagnosis Registry, called Patobank, and in the Danish 
National Hospital Registry,1 which contains information 
on all hospital admissions for somatic diseases and the 
Danish Civil Registration System (CRS),2 established in 
1968 to register all individuals alive and living in Denmark 
by a unique personal identification number. Mismatch will 
be annotated, and the relevant departments will be asked 
to ensure registration of any missing patients. Treatment 
of MM has improved by the introduction of high-dose 
chemotherapy with autologous stem cell support in the 
90s3,4 and by the introduction of thalidomide, bortezomib, 
and new immunomodulatory drugs such as lenalidomide 
and pomalidomide.5–7 Several new drugs are in the pipeline 
and are expected to be approved soon.8–10 The clinical trials 
leading to approval of new drugs are based on the studies 
of selected myeloma populations with strict exclusion cri-
teria regarding age, performance status, comorbidity, and 
disease complications, eg, renal insufficiency. The new 
treatment options are expensive, and there is an increasing 
demand for documentation of the impact of antineoplastic 
treatment and supportive care, such as bisphosphonates, 
vertebroplasty, and erythropoietin. The database will be 
able to contribute in this context with population-based 
data from daily clinical practice.
The database does not register comorbidity. However, 
these data can be captured from the Danish National Hospital 
Registry, which includes information on all hospital admis-
sions in Denmark since 1977 and all contacts to emergency 
rooms or outpatient clinics since 1995. Since 1994, diagnostic 
information on each contact with the hospital has been coded 
by physicians according to the International Classification 
of Diseases, Tenth Edition system.1 Data on drug use can be 
obtained from the Danish prescription registry.11 Status on 
working capability can be captured from the employment 
databases, and information on granted disability pension 
can be obtained from the Danish Register for Evaluation 
of Marginalization (DREAM), which is based on data from 
the Danish Ministry of Employment, the Danish Ministry 
of Education, CRS, and SKAT (the Danish tax  authority).12 
DREAM includes data on all Danish citizens who have 
received welfare benefits, since 1991. Each person is reg-
istered with a code indicating the type of welfare benefit 
received. DREAM has 100% coverage of those granted 
disability pension in Denmark since 2000. Thus, due to the 
unique Danish personal identification number, the combined 
use of a number of National registries allows scientific analy-
ses on a number of socioeconomic factors, health care use, 
comorbidity factors, etc.
The Danish National Cancer Biobank was established 
in 2009,13 and the hematological cancers became part of 
this biobank in 2012. From newly diagnosed patients with 
myeloma, serum, plasma, DNA, bone marrow plasma, and 
bone marrow mononuclear cells or immunomagnetically 
separated CD138-positive cells and the CD138 negative 
fraction of cells have been frozen. Bone marrow and blood 
have also been sampled from some patients at first relapse 
or disease progression. Information on biobanked material 
is registered in the clinical database; thereby the clinical 
database and cancer biobank form the basis for population-
based translational research.
The Danish Cancer Registry registers all malignances and 
premalignances in Denmark, including the same diagnoses 
as the specified myeloma registry. This is done in parallel 
with the MM registry and without any formal collaboration 
but based on the same data sources. The broad epidemiologi-
cal cancer registry does not record clinical information on 
disease complications, given treatment, treatment responses, 
response duration, etc. Moreover, it does not record informa-
tion on biobanked material.
Study population
All newly diagnosed patients with MM, SMM, PCL, and 
osseous and extraosseous solitary plasmacytoma have been 
registered since January 1, 2005. At progression from SMM 
or solitary plasmacytomas to MM, patients are re-registered 
with data from time of transformation. POEMS syndrome 
(polyneuropathy, organomegali, endocrinopathy, monoclonal 
gammopathy and skin changes syndrome), amyloid Light-
chain amyloidosis, monoclonal gammopathy of undetermined 
significance (MGUS), and MGUS with polyneuropathy have 
been registered in the database since January 1, 2014.
The Danish population is 5.5 million. Approximately 290 
patients are diagnosed annually with MM, either as de novo 
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or as progression from known MGUS, SMM, or solitary 
plasmacytoma.
In Denmark, treatment of hematological diseases is 
centralized to nine hematological departments. Six univer-
sity hospitals perform high-dose treatment with autologous 
stem cell support and radiotherapy, and two centers perform 
allogeneic hematopoietic stem cell transplantation. All 
treatments are paid for by the public health care system. 
No hematological patients are treated in private hospitals 
or clinics.
Since 2009, the DMSG has developed nationwide clinical 
guidelines for diagnosis and treatment. The guideline for MM 
is revised annually. Most hematological clinics participate 
in clinical trials conducted by DMSG, the Nordic Myeloma 
Study Group (NMSG), or by the European Myeloma 
 Network (EMN). Up to June 30, 2015, the following num-
bers of patients were registered in the registry: 2,907 MM 
patients, 485 SMM, 64 primary PCL, 103 solitary bone 
 plasmacytomas, and 88 extraosseous plasmacytomas.
The age-dependent overall survival of MM patients in 
the registry is shown in Figure 1. As expected, there is a 
large difference in overall survival according to age. In MM 
patients <60 years, the median survival exceeds 72 months, 
whereas it is <24 months for patients >80 years.
Variables
The main registered variables at diagnosis are shown in 
Table 1. All data are registered electronically on a central 
server owned by the Danish Health Regions. More than 
95% are usually registered in the database within the first 
year after diagnosis, and after 2 years, the completeness is 
almost 100%.
In 2013–2014, DMSG performed a data validation study 
of registered data in the database. Ten percent of the regis-
tered patients at each department were randomly selected for 
independent on-site monitoring. A skilled trainee in hema-
tology compared registered data with the patients’ medical 
records. In cases of inconsistency, a DMSG evaluation 
Figure 1 Age-dependent overall survival of 2,907 newly diagnosed Danish patients with symptomatic multiple myeloma.
Notes: The patients were registered in the Danish National Multiple Myeloma Registry between January 1, 2005, and June 30, 2015. Median follow-up is 59.5 months. The 
completeness of the registry is ~100%, and the survival curves therefore present “real life data” on multiple myeloma survival in the whole population.
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 committee was consulted. Typical recurrent problems were 
that a given parameter at diagnosis, eg, serum C-reactive 
protein, was not taken at the date of diagnosis, which is 
defined as the date of bone marrow biopsy or tumor biopsy, 
but 10 days prior and that registered hemoglobin value was 
the value obtained after blood transfusion. The DMSG evalu-
ation committee deemed these inconsistencies to be of minor 
importance. Overall, each parameter was correct in >95% 
of the cases, and the evaluation committee concluded that 
quality of data is high.
Follow-up
The flow in registrations is illustrated in Table 2. The regis-
tration sheet is filled in at diagnosis. It includes a summary 
of planned treatments and supportive care, eg, planned 
first-line therapy with cyclophosphamide–bortezomib– 
dexamethasone, stem cell harvest, and high-dose melphalan 
with stem cell support combined with radiation therapy and 
treatment with bisphosphonate.
The actual received first-line regimen and supportive 
treatment and achieved response to first-line treatment are 
reported in the first-line treatment form at response evalua-
tion after end of first-line treatment.
Progression-free survival, time to next treatment, second-
line treatment regimen, and response to second-line treatment 
are reported on the second-line treatment form at response 
evaluation after end of second-line treatment. This scheme 
also includes information on type of relapse, eg, clinical 
relapse with progressive bone disease or renal failure, or 
paraclinical relapse with rise in M-component levels.
A follow-up scheme is reported at time of death or may be 
reported prior to death at the discretion of the department or 
physician. It includes a summary of the number of treatment 
lines administered and cause of death.
Examples of research
The annual DMMR reports from DMSG have documented 
high early mortality in newly diagnosed frail and elderly 
patients with MM ineligible for high-dose chemotherapy. 
Particularly, for the elderly population older than 80 years, the 
registry documents a high early mortality rate as illustrated in 
Figure 1. In an analysis of patients registered in 2005–2012, 
Table 2 Main registered parameters concerning treatment, response to treatment and course of disease in multiple myeloma, plasma 
cell leukemia, and solitary plasmacytoma in the Danish National Multiple Myeloma Registry
At diagnosis First-line treatment Second-line treatment Follow-up
Planned antimyeloma regimen
Planned radiotherapy
Planned bisphosphonates
Received first-line treatment regimen
Date for start and end of treatment
Best response according to IMWG 
criteria
Date of disease progression after first-line therapy (PFS1)
Type of progression
Received second-line treatment regimen
Date for start and end of second-line treatment
Best response according to IMWG criteria
Disease status
Number of lines of 
treatment regimens
Date of death
Cause of death 
Abbreviations: IMWG, International Myeloma Working Group; PFS1, first progression-free survival.
Table 1 Main registered baseline parameters at diagnosis in multiple myeloma, smoldering MM, plasma cell leukemia, and solitary 
plasmacytoma in the Danish National Multiple Myeloma Registry
Patient related Myeloma clonal characteristics Myeloma complications Prognostical 
parameters
Age
Sex
Personal identification 
number
Postal code
Date of diagnosis
M-component subtype
S-M-component concentration
U-M-component concentration
Light-chain subtype
S-free light kappa lambda chain concentration and ratio
Bone marrow plasma cell infiltration (%)
Cytogenetics
Karyotype
FISH abnormalities
Paraclinical findings
Bone disease by skeletal survey
CT/MRI/PET/DEXA (if performed)
Calcium
Creatinine
Hemoglobin
Leukocyte count
Thrombocyte count
U-protein
Clinical complications
Medullary compression
Bone fractures
Hemodialysis-dependent renal failure
Amyloidosis
Polyneuropathy
ISS
Beta-2-microglobulin
Albumin
WHO performance status
LDH
CRP
Abbreviations: CRP, C-reactive protein; CT, computed tomography; DEXA, dual-energy X-ray absorptiometry; FISH, fluorescence in situ hybridization; ISS, International 
Staging System; LDH, lactate dehydrogenase; MM, multiple myeloma; MRI, magnetic resonance imaging; PET, positron emission tomography; WHO, World Health Organization.
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330 patients (22.0%) out of 1,497 transplant ineligible 
patients died within 6 months of diagnosis. A skilled trainee 
reviewed all cases on-site. The majority of early deaths 
(50.9%) were caused by infections.14 As a consequence 
of these findings, DMSG started, in 2013, a randomized, 
controlled clinical trial to study the efficacy of prophylactic 
antibiotics within the first 6 months of diagnosis in elderly 
patients with MM (EudraCT number: 2012-004424-38).
Administrative issues and funding
The DMMR is owned and financed by the Danish Health 
Regions. The server is placed at and run by IT support from 
Competence Centre East in Copenhagen. Statisticians and 
clinical epidemiologists are used at the Competence Centre. 
Scientific hematological expertise and an administrative 
secretary are connected part time. A DMSG database com-
mittee reviews, comments, and writes the annual reports in 
collaboration with an epidemiologist and a statistician from 
the Competence Centre.
Conclusion
The DMMR is a population-based database eligible for 
clinical, epidemiological, and translational research. The 
database has a very high registration completeness, and a 
data validation study has shown high-quality data.
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